Xueba’s medical black technology system

Chapter 143 First Generation PD-1TIGIT Inhibitors

After sorting out all the consumables that might be used in the experiment, Lu Liang breathed a sigh of relief.

Wang Wentao came over at this time and said, "Senior brother, is there anything else you want to prepare?"

Lu Liang shook his head: "That's almost it. Everything is here."

Wang Wentao hesitated: "Then if there is nothing else, I will leave first."

"Okay, you go back to the study room first."

After Wang Wentao left the laboratory, Lu Liang moved a box full of test consumables under the experimental table.

After doing all this, Lu Liang also closed the door of the laboratory and left the laboratory.

On the way back to the dormitory, Lu Liang couldn't help but think about it.

Now that the consumables are ready, it's time to analyze the medicine.

Thinking of this, Lu Liang couldn't help but speed up his pace.

After returning to the dormitory and taking a simple shower, Lu Liang sat down at his desk and prepared to analyze the medicine.

Regarding this analysis, Lu Liangliang was actually quite uneasy.

Because, compared to the previous analysis, what he analyzed this time was a drug that had never existed before.

Therefore, it is unknown what kind of medicine the system can analyze for him.

As Lu Liang's thoughts moved, the system panel appeared in front of Lu Liang's eyes.

After seeing the information on the system panel, Lu Liang couldn't help but widen his eyes.

[Level: lv5]

[Analysis target: PD-1/TIGIT inhibitor]

[It can simultaneously inhibit the activation of two different immune checkpoints, PD-1 and TIGIT. By inhibiting immune checkpoints, it can greatly regulate the lethality of many immune cells such as T cells and NK cells. 】

[Source points required for analysis: 5]

[Existing source point: 6.2]

[There are currently no PD-1/TIGIT inhibitors, and the analysis can be obtained directly. 】

[Start parsing? 】

Lu Liang didn't hesitate at all, he directly chose analysis.

And as Lu Liang's thoughts moved, he felt a torrent of information pouring into his head.

After digesting and absorbing all the information, Lu Liang suddenly opened his eyes, and his gaze suddenly became fiery.

Sure enough, monoclonal antibodies!

This was exactly what he expected.

After being injected into the body, this antibody will bind to the PD-1 and TIGIT immune checkpoints on the surface of immune cells, which is equivalent to blocking these two immune checkpoints.

The receptor proteins produced by tumor cells can no longer activate immune checkpoints to escape.

Lu Liang breathed a long sigh of relief, then he turned on his computer, created a new document, and recorded the method of preparing monoclonal antibodies in detail.

It lasts into the evening.

Lu Liang typed the last word heavily on the keyboard, then raised his head from the screen.

Then he rubbed his slightly sore neck. After taking a long breath, he looked at the two completed documents on the screen.

Among the two documents, one is a patent application and the other is the preparation method of PD-1/TIGIT monoclonal antibody drug.

After completing the submission of the patent application, Lu Liang sent the inhibitor preparation method to Tian Li.Tian Li quickly replied to the message.

Compared with before, Tian Li was now particularly skilled. After reading the message Lu Liang sent him, he did not ask about the function of the medicine, but just asked how long it would take.

"Of course, the sooner the better."

Lu Liang's reply was also simple and clear.

"Okay, I'll make arrangements as soon as possible." Tian Li simply replied, and then went to work.

After getting Tian Li's reply, Lu Liang looked at the computer screen again. He was going to sort out the documents he had read before and write a review.

After all, five source points were suddenly spent. Lu Liang said that he didn't feel bad, which was simply impossible.

Therefore, how to complete these source points next is the most important thing for Lu Liang.

Lu Liang created a new document again. After thinking for a moment, he typed a line on the blank document.

"Research Progress of PD-1 and TIGIT Immune Checkpoint in the Treatment of Non-Small Cell Lung Cancer"

In the city center, in thousands of five-star hotels.

In the magnificent large lecture hall, a press conference was held this time.

The protagonist of this press conference is a new drug from Moco Company for the treatment of lung cancer-sugalimab.

At this moment, there was already a huge crowd in the audience. In addition to reporters, there were also a large number of friends and suppliers.

On the stage is a huge LED screen, which is playing promotional images of Moco Company in a loop. The tall factory also has close-up images of their new drug sugalimab.

On the stage was an older man in a straight suit. This man was Dai Yang, the chairman of Moco's domestic branch.

At this moment, Dai Yang had a bright smile on his face, and beside him was a slightly old man in his 50s.

The man looked excited at the moment, he took the microphone and said.

"Dear friends, I am a 58-year-old lung cancer patient. In May last year, I was diagnosed with advanced lung cancer by the doctor."

"The doctor used targeted drugs to treat me. After three months of treatment, my lung cancer showed a slight improvement."

"But unfortunately, as the cancer cells in my body developed drug resistance, those targeted drugs gradually stopped working on me, and my condition worsened again."

"Just in February this year, the doctor told me that I can only take conservative treatment measures because I may only have less than five months left."

At this point, the man began to burst into tears.

Everyone in the audience was also talking about it. After all, a grown man could cry like this in front of so many people. You can imagine how much psychological pressure he must have felt at that time.

I don’t know who took the lead in applauding, and soon the audience burst into applause, which seemed to comfort the man.

After hearing the warm applause from the audience, the man suddenly became energetic. He quickly wiped away the tears from the corners of his eyes and said with a loud voice and an excited expression.

"However, fortunately at this time, I suddenly learned that Moco's new anti-lung cancer drug sugalumab has recently been launched, which rekindled my hope again."

"After receiving sugalimab treatment, the doctor told me that the lung cancer cells in my body have been effectively controlled."

"The doctor said that I only need to take medicine on time and my condition can be controlled."

"I am now grateful to Moco and its sugalimab drug. They gave me another life."

The man's expression was uplifting, and it was easy to tell from his loud voice and healthy complexion that he was now very nervous and did not look like a patient at all.

This greatly proves the effectiveness of sugalimab.

As the man finished speaking, the audience burst into warm applause.

(End of this chapter)